Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 3Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 31OTHER 18NETWORK 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Breast Neoplasms 2Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × Everolimus × Clear all
NCT01674140 2026-02-10

e3

SWOG Cancer Research Network

Phase 3 Active not recruiting
1,939 enrolled 15 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01120249 2025-09-16

S0931

SWOG Cancer Research Network

Phase 3 Completed
1,545 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02137837 2021-01-28

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

SWOG Cancer Research Network

Phase 3 Terminated
37 enrolled 16 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡